CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: C3orf38 (ImmuneEditome ID:285237)

1. Gene summary of enriched editing regions for C3orf38

check button Gene summary
Gene informationGene symbol

C3orf38

Gene ID

285237

GeneSynonyms-
GeneCytomap

3p11.1

GeneTypeprotein-coding
GeneDescriptionuncharacterized protein C3orf38|dense incisors
GeneModificationdate20230517
UniprotIDQ5JPI3;E9PFZ1
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr3:88163275-88164843:+ENST00000485219.1ENSG00000179021.8C3orf38ncRNA_intronicAluSg,L2a,L2c,AluSq,AluYm1chr3:88163275-88164843:+.alignment
chr3:88166003-88167212:+ENST00000485219.1ENSG00000179021.8C3orf38ncRNA_intronicAluSg,Charlie25,AluSx1chr3:88166003-88167212:+.alignment


Top

2. Tumor-specific enriched editing regions for C3orf38


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr3:88163275-88164843:+BLCAPathEER5.4990e-032.8772e-030.6306image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for C3orf38


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr3:88166003-88167212:+THYMEERENSG00000272455,RP4-758J18.13-0.44431.0066e-036.1472e-05-0.4228imageNEIF4A3;HNRNPC;NOP56;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_DNA_REPAIR
chr3:88166003-88167212:+THYMEERENSG00000126882,FAM78A-0.44481.0786e-031.0533e-06-0.5035imageNEIF4A3;ELAVL1;FUS;HNRNPC;HNRNPK;IGF2BP2;NOP56;NOP58;TAF15;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY
chr3:88166003-88167212:+THYMEERENSG00000270956,RP11-65L3.4-0.44511.2189e-031.3750e-05-0.4550imageNEIF4A3;ELAVL1;FUS;HNRNPC;HNRNPK;IGF2BP2;NOP58;RBM47;TAF15;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_E2F_TARGETS
chr3:88166003-88167212:+THYMEERENSG00000175826,CTDNEP1-0.40293.0297e-038.3341e-06-0.4650imageNEIF4A3;ELAVL1;FUS;HNRNPC;HNRNPK;IGF2BP2;NOP56;NOP58;RBM47;TAF15;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_DNA_REPAIR
chr3:88166003-88167212:+THYMEERENSG00000100365,NCF4-0.39403.8782e-032.8964e-06-0.4852imageNFUS;TAF15NCF4T_cells_CD4_memory_activatedGSVA_HALLMARK_ALLOGRAFT_REJECTION
chr3:88166003-88167212:+THYMEERENSG00000171148,TADA3-0.38234.0663e-031.3990e-04-0.4037imageNEIF4A3;ELAVL1;FUS;HNRNPC;HNRNPK;IGF2BP2;NOP56;NOP58;TAF15;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_PROTEIN_SECRETION
chr3:88166003-88167212:+THYMEERENSG00000102390,PBDC1-0.37584.5626e-031.2716e-05-0.4566imageNEIF4A3;ELAVL1;HNRNPC;IGF2BP2;NOP56;NOP58;RBM47;TAF15;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_DNA_REPAIR
chr3:88166003-88167212:+THYMEERENSG00000150977,RILPL2-0.39164.9594e-032.9025e-05-0.4393imageNEIF4A3;ELAVL1;FUS;HNRNPC;HNRNPK;IGF2BP2;NOP56;NOP58;RBM47;TAF15;U2AF2NAT_cells_CD4_memory_activatedGSVA_HALLMARK_COMPLEMENT
chr3:88166003-88167212:+THYMEERENSG00000185670,ZBTB3-0.39265.0608e-033.7685e-05-0.4337imageNEIF4A3;ELAVL1;FUS;HNRNPC;IGF2BP2;NOP56;TAF15;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY
chr3:88166003-88167212:+THYMEERENSG00000131748,STARD3-0.39245.2175e-035.1683e-06-0.4743imageNEIF4A3;ELAVL1;FUS;HNRNPC;HNRNPK;IGF2BP2;NOP56;NOP58;TAF15;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_PROTEIN_SECRETION

More results



Top

4. Enriched editing regions and immune related splicing for C3orf38


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000179021.8,C3orf38
ESCAEAGESENSG00000126091.15chr143838218:43838311:43879334:43879507:43894382:438944770.29813.4767e-021.3131e-050.4329imageNBCCIP;CELF2;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;DICER1;EIF4A3;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR2;HNRNPA1;HNRNPC;HNRNPD;HNRNPL;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;LIN28A;LIN28B;MBNL2;MOV10;MSI1;MSI2;NOP56;NOP58;NPM1;PRPF8;PTBP1;QKI;RBFOX2;RBM10;RBM47;SAFB2;SRSF1;SRSF10;SRSF3;SRSF7;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF2;UPF1;YTHDC1;YTHDF1;ZC3H7BNANK_cells_activatedGSVA_HALLMARK_COAGULATION
ENSG00000179021.8,C3orf38
THYMEAGESENSG00000182944.13chr2229288767:29288786:29291564:29291599:29292136:29292169-0.38963.5605e-021.6118e-04-0.4003imageNALYREF;BCCIP;BUD13;CELF2;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;DICER1;EIF4A3;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NOP56;NOP58;NPM1;NUMA1;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM47;RNF219;SAFB2;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1;ZC3H7B;ZNF184NAMacrophages_M2GSVA_HALLMARK_E2F_TARGETS
chr3:88166003-88167212:+
THYMEERIRENSG00000121310.12chr152911722:52911790:52912753:529128300.38582.4197e-025.7418e-050.4648imageNEIF4A3;ELAVL1;FUS;HNRNPC;HNRNPK;NOP56;NOP58;TAF15;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_DNA_REPAIR
chr3:88166003-88167212:+
THYMEERIRENSG00000137312.10chr630740678:30740798:30741195:30741333-0.20142.7753e-027.0190e-05-0.4939imageNEIF4A3;ELAVL1;FUS;HNRNPC;HNRNPK;IGF2BP2;NOP56;NOP58;TAF15;U2AF2NANK_cells_resting
chr3:88166003-88167212:+
THYMEERESENSG00000160226.11chr2144333032:44333262:44334060:44335804:44337648:443376670.34162.6683e-022.4408e-040.4339imageNEIF4A3;ELAVL1;FUS;HNRNPC;HNRNPK;IGF2BP2;NOP56;NOP58;TAF15;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING
chr3:88166003-88167212:+
THYMEERMEXENSG00000130165.6chr1911554231:11554365:11554835:11554946:11555173:11555255:11559190:115592230.33254.7258e-026.4815e-040.4151imageNEIF4A3;ELAVL1;FUS;HNRNPC;HNRNPK;IGF2BP2;NOP56;NOP58;TAF15;U2AF2NAMacrophages_M2GSVA_HALLMARK_UV_RESPONSE_DN
ENSG00000179021.8,C3orf38
THYMEAGIRENSG00000221988.8chr632162567:32162622:32162806:321636750.38542.6036e-021.7157e-040.4105imageNBCCIP;BUD13;CELF2;CSTF2T;DDX3X;DGCR8;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NOP56;NOP58;NPM1;NUMA1;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RNF219;SAFB2;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1;ZNF184NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_DNA_REPAIR
chr3:88166003-88167212:+
THYMEERESENSG00000182944.13chr2229288767:29288786:29291564:29291599:29292136:29292169-0.39293.4181e-021.2253e-04-0.4115imageNEIF4A3;ELAVL1;FUS;HNRNPC;HNRNPK;IGF2BP2;NOP56;NOP58;RBM47;TAF15;U2AF2NAMacrophages_M2GSVA_HALLMARK_E2F_TARGETS
chr3:88166003-88167212:+
THYMEERIRENSG00000242028.1chr1543800598:43800784:43801517:438030430.44419.9237e-033.1155e-050.4378imageNEIF4A3;ELAVL1;FUS;HNRNPC;HNRNPK;IGF2BP2;NOP56;NOP58;RBM47;TAF15;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_HEDGEHOG_SIGNALING
ENSG00000179021.8,C3orf38
THYMEAGIRENSG00000242028.1chr1543800598:43800784:43801517:438030430.40392.6091e-029.0320e-050.4095imageNBCCIP;BUD13;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LIN28;LIN28B;LSM11;MOV10;MSI1;MSI2;NOP56;NOP58;NPM1;NUMA1;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM47;RNF219;SAFB2;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1;ZNF184NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_HEDGEHOG_SIGNALING

More results



Top

5. Enriched editing regions and immune infiltration for C3orf38


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr3:88166003-88167212:+BLCAEERMacrophages_M11.6661e-020.2121image
ENSG00000179021.8,C3orf38BLCAEAGT_cells_CD4_naive1.2045e-02-0.2222image
ENSG00000179021.8,C3orf38COADEAGB_cells_memory5.8843e-030.5251image
ENSG00000179021.8,C3orf38DLBCEAGMacrophages_M01.9595e-030.6229image
chr3:88166003-88167212:+ESCAEERB_cells_naive1.4493e-02-0.4218image
ENSG00000179021.8,C3orf38ESCAEAGB_cells_memory1.9318e-020.2188image
ENSG00000179021.8,C3orf38KIRCEAGMonocytes2.8412e-020.2984image
ENSG00000179021.8,C3orf38LAMLEAGNeutrophils7.5043e-030.4383image
chr3:88166003-88167212:+LUADEERMonocytes4.2497e-020.2628image
ENSG00000179021.8,C3orf38LUADEAGMonocytes1.6031e-020.2977image
ENSG00000179021.8,C3orf38LUSCEAGT_cells_CD4_memory_activated2.5874e-020.4205image
ENSG00000179021.8,C3orf38MESOEAGB_cells_naive1.2254e-030.6438image
chr3:88163275-88164843:+OVEERNK_cells_activated3.5579e-02-0.1889image
ENSG00000179021.8,C3orf38OVEAGMacrophages_M09.5094e-030.2084image
ENSG00000179021.8,C3orf38PAADEAGNK_cells_resting3.8847e-020.3458image
chr3:88166003-88167212:+PCPGEERB_cells_naive2.6279e-02-0.2996image
ENSG00000179021.8,C3orf38PCPGEAGB_cells_naive1.3679e-02-0.3044image
chr3:88163275-88164843:+STADEERNK_cells_resting5.5932e-040.2198image
ENSG00000179021.8,C3orf38STADEAGNK_cells_resting2.9487e-030.1830image
ENSG00000179021.8,C3orf38TGCTEAGMacrophages_M15.5711e-030.4356image
chr3:88166003-88167212:+THCAEERT_cells_CD4_memory_resting3.6028e-020.1614image
chr3:88166003-88167212:+THYMEERMacrophages_M24.0990e-040.3769image
ENSG00000179021.8,C3orf38THYMEAGMacrophages_M21.1038e-030.3460image


Top

6. Enriched editing regions and immune gene sets for C3orf38


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
ENSG00000179021.8,C3orf38UCECEAG5.0398e-030.36664.4684e-020.26703.1876e-030.38403.0062e-020.2876image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000179021.8,C3orf38ACCGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG4.3326e-02-0.4248image
chr3:88166003-88167212:+BLCAGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER3.3119e-040.3136image
chr3:88163275-88164843:+BLCAGSVA_HALLMARK_APICAL_SURFACEEER1.9686e-020.5166image
ENSG00000179021.8,C3orf38BLCAGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG1.9297e-040.3250image
ENSG00000179021.8,C3orf38BRCAGSVA_HALLMARK_PROTEIN_SECRETIONEAG3.8651e-050.2582image
ENSG00000179021.8,C3orf38DLBCGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG8.3077e-050.7398image
ENSG00000179021.8,C3orf38ESCAGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG3.1933e-020.2011image
chr3:88166003-88167212:+ESCAGSVA_HALLMARK_PANCREAS_BETA_CELLSEER2.2214e-02-0.3969image
ENSG00000179021.8,C3orf38GBMGSVA_HALLMARK_PROTEIN_SECRETIONEAG2.0800e-020.2321image
ENSG00000179021.8,C3orf38HNSCGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG1.9797e-03-0.5117image
ENSG00000179021.8,C3orf38KIRCGSVA_HALLMARK_SPERMATOGENESISEAG2.9524e-040.4739image
ENSG00000179021.8,C3orf38KIRPGSVA_HALLMARK_GLYCOLYSISEAG7.9220e-030.3064image
ENSG00000179021.8,C3orf38LGGGSVA_HALLMARK_DNA_REPAIREAG3.6943e-04-0.2285image
chr3:88166003-88167212:+LUADGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER4.4875e-020.2600image
ENSG00000179021.8,C3orf38LUSCGSVA_HALLMARK_APICAL_SURFACEEAG1.1586e-030.5820image
ENSG00000179021.8,C3orf38MESOGSVA_HALLMARK_P53_PATHWAYEAG1.5266e-03-0.6342image
ENSG00000179021.8,C3orf38PAADGSVA_HALLMARK_ANGIOGENESISEAG1.5006e-020.4023image
ENSG00000179021.8,C3orf38PCPGGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.8393e-020.2917image
ENSG00000179021.8,C3orf38PRADGSVA_HALLMARK_DNA_REPAIREAG2.7682e-03-0.2906image
ENSG00000179021.8,C3orf38SARCGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.8292e-020.2601image
chr3:88166003-88167212:+STADGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER4.8427e-02-0.2287image
chr3:88163275-88164843:+STADGSVA_HALLMARK_UV_RESPONSE_DNEER6.8299e-04-0.2164image
ENSG00000179021.8,C3orf38STADGSVA_HALLMARK_UV_RESPONSE_DNEAG2.4840e-04-0.2245image
ENSG00000179021.8,C3orf38TGCTGSVA_HALLMARK_G2M_CHECKPOINTEAG4.2095e-030.4483image
ENSG00000179021.8,C3orf38THCAGSVA_HALLMARK_ANDROGEN_RESPONSEEAG4.8828e-040.2616image
chr3:88166003-88167212:+THCAGSVA_HALLMARK_MTORC1_SIGNALINGEER8.8453e-030.2008image
ENSG00000179021.8,C3orf38THYMGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG5.0557e-05-0.4226image
chr3:88166003-88167212:+THYMGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER2.1944e-05-0.4453image
ENSG00000179021.8,C3orf38UCECGSVA_HALLMARK_MTORC1_SIGNALINGEAG6.3182e-040.4392image


Top

7. Enriched editing regions and drugs for C3orf38


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr3:88166003-88167212:+BLCACMKEER3.5190e-04-0.3122image
chr3:88163275-88164843:+BLCAJNK.9LEER2.7890e-020.4911image
ENSG00000179021.8,C3orf38BLCACMKEAG3.2317e-05-0.3600image
ENSG00000179021.8,C3orf38BRCABryostatin.1EAG2.1224e-060.2958image
ENSG00000179021.8,C3orf38DLBCA.770041EAG1.3829e-03-0.6385image
ENSG00000179021.8,C3orf38ESCAAKT.inhibitor.VIIIEAG2.1240e-02-0.2156image
chr3:88166003-88167212:+ESCAJNK.Inhibitor.VIIIEER5.3080e-03-0.4742image
ENSG00000179021.8,C3orf38HNSCBMS.509744EAG1.5417e-030.5220image
ENSG00000179021.8,C3orf38KIRPAUY922EAG1.9417e-030.3545image
ENSG00000179021.8,C3orf38LAMLAS601245EAG1.3644e-020.4074image
ENSG00000179021.8,C3orf38LGGBMS.509744EAG1.1825e-040.2465image
chr3:88166003-88167212:+LUADElesclomolEER1.6786e-02-0.3077image
ENSG00000179021.8,C3orf38LUADElesclomolEAG3.1788e-02-0.2666image
ENSG00000179021.8,C3orf38LUSCBortezomibEAG2.0865e-03-0.5568image
ENSG00000179021.8,C3orf38MESOGefitinibEAG2.3205e-020.4817image
chr3:88163275-88164843:+OVJNK.9LEER1.8728e-040.3294image
ENSG00000179021.8,C3orf38OVA.443654EAG1.6313e-020.1933image
ENSG00000179021.8,C3orf38PAADAKT.inhibitor.VIIIEAG1.2195e-02-0.4251image
ENSG00000179021.8,C3orf38PCPGCamptothecinEAG1.0754e-030.3965image
chr3:88166003-88167212:+PCPGCamptothecinEER1.9836e-040.4814image
ENSG00000179021.8,C3orf38PRADGW843682XEAG2.6060e-030.2923image
ENSG00000179021.8,C3orf38SARCAKT.inhibitor.VIIIEAG2.2763e-04-0.3964image
ENSG00000179021.8,C3orf38SKCMCHIR.99021EAG2.6035e-04-0.4262image
chr3:88166003-88167212:+STADGDC0941EER5.9261e-03-0.3149image
chr3:88163275-88164843:+STADAZD6482EER1.2663e-030.2056image
ENSG00000179021.8,C3orf38STADGW.441756EAG1.1431e-04-0.2361image
ENSG00000179021.8,C3orf38TGCTBAY.61.3606EAG1.4130e-03-0.4934image
ENSG00000179021.8,C3orf38THCABMS.708163EAG9.0221e-04-0.2494image
chr3:88166003-88167212:+THCAGSK.650394EER2.1430e-040.2811image
ENSG00000179021.8,C3orf38THYMAZD8055EAG2.7496e-050.4357image
chr3:88166003-88167212:+THYMAZD8055EER2.6560e-050.4412image
ENSG00000179021.8,C3orf38UCECAUY922EAG2.0430e-02-0.3064image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType